Critical Outcome Technologies - May 2014

1,065 views
970 views

Published on

Investor presentation for Critical Outcome Technologies (TSXV: COT), highlighting the Company's lead cancer drug candidate and its small molecule profiling and investment due diligence tool, CHEMFirm.

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,065
On SlideShare
0
From Embeds
0
Number of Embeds
520
Actions
Shares
0
Downloads
3
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Critical Outcome Technologies - May 2014

  1. 1. Investor Presentation | May 2014 The future of drug discovery has arrived Reducing development time, cost & risk
  2. 2. 2TSXV: COT When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward- looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI). COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission. All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation. Disclaimer
  3. 3. 3TSXV: COT 3TSXV: COT Critical Outcome Technologies Inc. 3  A bioinformatics company focused on efficient and accelerated drug discovery  Listed on the TSX-V under the symbol COT since 2006
  4. 4. 4TSXV: COT Investment highlights 1 2 3 We reduce the time, cost & risk of bringing new drugs to market Potential cancer breakthrough drug candidate is nearly Phase 1 ready We have many more revenue opportunities in our pipeline
  5. 5. 5TSXV: COT Conventional drug development is a long & expensive process characterized by a high risk of failure 11 – 15 years $1 billion or more 1 FDA approval 5
  6. 6. 6TSXV: COT What we do  Reduce drug discovery, optimization & lead selection by 1.5 to 3 yrs.  Saving significant $$$  Increasing revenue period under patent protection
  7. 7. 7TSXV: COT How we do it – CHEMSAS® 7TSXV: COT Proprietary, artificial intelligence based drug discovery platform technology
  8. 8. 8TSXV: COT Failed attempts occur quickly & cheaply in computer simulations, not the ‘wet lab’ Higher probability of clinical & commercial success Computational replication of traditional ‘wet lab’ drug discovery process 8 Advantages of CHEMSAS® TSXV: COT
  9. 9. 9TSXV: COT Potential cancer breakthrough Our lead compound, COTI-2, is effective against many human cancers with mutations of the p53 gene
  10. 10. 10TSXV: COT Why COTI-2 is exciting  > 50% of all human cancers have a p53 mutation (eg. ~ 95% of serous ovarian cancers)  Mechanism of action confirmed by thought leader Dr. Gordon Mills at MD Anderson Cancer Center (June 2013)  Novel, first-in-class  Strong IP protection in place
  11. 11. 11TSXV: COT COTI-2 soon to be Phase 1 ready  In final 2-species toxicity studies – completion in first half of 2014 (dosing completed)  FDA IND filing expected in September of 2014 (leading to Phase 1 clinical trial)  Pursuing orphan drug and/or breakthrough therapy status  Signed an LOI with a potential strategic partner, Portage Biotech Inc., for clinical development
  12. 12. 12TSXV: COTTSXV: COT COTI-2 = significant revenue potential  Top 5 2012 Phase 1/2 oncology licensing deals disclosed (1):  Upfront payments of approx. $25-$92 million  Milestone payments between $550-$1,100 million  Royalties on net sales  1st half of 2013 (2) – 16 Phase 1 licensing deals with 6 in cancer – avg. upfront $30m (1) Medius Associates (2) Thomson Reuters
  13. 13. 13TSXV: COT Other revenue opportunities  Robust internal pipeline of drug candidates - AML, MRSA, colorectal and other cancers, MS, etc.  3 existing R&D collaborations expected to bring in milestone payments beginning late 2014 / 2015 - Western University - Delmar Chemicals - Major Pharma Co.
  14. 14. 14TSXV: COTTSXV: COT  A small molecule profiling & investment due diligence tool leveraging CHEMSAS®  Provides detailed report on compound attributes and specific areas for further assessment  Identifies properties outside the optimal range that may represent development challenges CHEMFirm
  15. 15. 15TSXV: COTTSXV: COT  Enables partners to make more knowledgeable investment decisions  Provides critical information for assessing both risk and value  Supports a “fail very early & very cheaply” drug investment strategy Benefits of CHEMFirm
  16. 16. 16TSXV: COT 16TSXV: COT Other future CHEMSAS® applications 16  Drug library profiling Based on customer identified criteria  Drug repurposing Finding new purposes for drugs coming off patent
  17. 17. 17TSXV: COT Summary 1 2 3 We reduce the time, cost & risk of bringing new drugs to market Potential cancer breakthrough drug candidate is nearly Phase 1 ready We have many more revenue opportunities in our pipeline
  18. 18. The future of drug discovery has arrived Reducing development time, cost & risk Dr. Wayne Danter President & CEO Tel: (519) 858-5157 wdanter@criticaloutcome.com www.criticaloutcome.com www.facebook.com/criticaloutcome twitter.com/criticaloutcome www.slideshare.net/criticaloutcome

×